Sherpa Healthcare Partners
VC Fund
Beijing, China
Sherpa Healthcare Partners is a VC fund in Beijing focused on Biotechnology and Health Care. Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.
- Total investments:
- 103
- Last investment:
- Lead investor:
- 28%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Sherpa Healthcare Partners invests in
Stages Sherpa Healthcare Partners invests in
Countries Sherpa Healthcare Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Round size
- Series A
- $7.2M–$50M
- Series B
- $15M–$100M
- Series C
- $21M–$128M
Investment Focus
Industry
- Biotechnology 38 (37%)
- Health Care 35 (34%)
- Medical 27 (26%)
- Pharmaceutical 14 (14%)
- Biopharma 10 (10%)
Stage
- Series A 33 (32%)
- Series B 24 (23%)
- Series C 13 (13%)
- Seed 8 (8%)
- Series D 5 (5%)
Country
- China 57 (55%)
- United States 15 (15%)
- Kenya 1 (1%)
- France 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Daqing Cai
founder and Managing partner
|
founder and Managing partner | Total investments: 6 | Find email | |
|
Darren Cai
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 2 | Find email | |
He Zhu
Vice President
|
Vice President | Total investments: 0 | Find email | |
|
Ouyang Xiangyu
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 0 | Find email | |
|
Shi Yina
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $120M / Series C / Aug 27, 2026 | ||
| ZSPepLib is a peptide lead drug developer, established in January 2017, coordinates Zhuzhou, Hunan. It is a platform-based company specializing in peptide lead drug discovery, focusing on the development, production, sales and new peptide drugs of the large-capacity peptide library. Screening R&D technical services. | $44.2M / Series C / May 11, 2026 | ||
| Avisi Technologies develops ophthalmic medical devices using nanotechnology to address vision loss associated with glaucoma and related eye conditions. The company designs implantable solutions such as VisiPlate, an aqueous shunt that regulates intraocular fluid through microchannel structures to help manage eye pressure. Its work combinesmaterials science and ophthalmology to create minimally invasive devices intended for long-term function within the eye. | $10.8M / Series A / Feb 25, 2026 | ||
Senas Medical
|
Senas Medical focuses on innovative cardiac electrophysiology solutions. | $14.3M / Series A / Jan 16, 2026 | |
| Spiro Medical is a medical device company developing a groundbreaking Pulmonary Neuromodulation (PNM) System for asthma treatment. The company offers a drug-free approach to controlling severe, chronic airway diseases through its Spiro Neuromodulation System. | $67M / Series A / Jan 07, 2026 | ||
Huihe Healthcare
|
Huihe Healthcare specializes in the development of medical devices for structural heart disease. The company was founded in 2019 and is headquartered in Shanghai, China. | Series D / Dec 27, 2025 | |
| Link Cell Therapies develops engineered cell therapy technologies intended to create targeted CAR T-based treatments for cancer. The company applies proprietary logic-gating methods that require co-expression of multiple cancer antigens to activate therapeutic T cells, aiming to focus immune cell activity on tumor cells while reducing effects onnon-cancerous tissues. Its work spans programs for solid tumors and certain hematologic cancers, with lead candidates progressing through preclinical development and preparation for clinical research. Link Cell Therapies also explores additional platforms and therapeutic programs that build on its core targeting technology to expand applications of engineered cellular therapies. | $60M / Series A / Dec 15, 2025 | ||
| Starna Therapeutics offers development of innovative drugs with RNA as the core, and has an industry-leading RNA and organ-selective delivery technology platform with independent intellectual property rights; the company has established a rich R&D pipeline , covering infectious disease vaccines, tumor immunity and other fields. | $42.1M / Series B / Oct 24, 2025 | ||
| AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $63M / Series B / Sep 21, 2025 | ||
| AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $50.3M / Series B / May 28, 2025 | ||
| See all 103 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sherpa Healthcare Partners invest in?
Sherpa Healthcare Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 103 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sherpa Healthcare Partners's check size?
Sherpa Healthcare Partners typically joins rounds of $7.2M–$50M at Series A, $15M–$100M at Series B and $21M–$128M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sherpa Healthcare Partners participates in.
How do I contact Sherpa Healthcare Partners?
Public channels for Sherpa Healthcare Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sherpa Healthcare Partners?
The team at Sherpa Healthcare Partners includes Daqing Cai (founder and Managing partner), Darren Cai (Founder & Managing Partner) and He Zhu (Vice President), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
